Literature DB >> 3393651

Recurrent rectal cancer: diagnosis with MR imaging versus CT.

G P Krestin1, W Steinbrich, G Friedmann.   

Abstract

During an 18-month period, a prospective study comparing the findings at computed tomography (CT) and magnetic resonance (MR) imaging was conducted on 35 patients who satisfied the following criteria: prior surgery for rectal cancer (11 curative resections, 24 rectal amputations), perineal pain and/or elevated carcinoembryonic antigen (CEA) level, and a soft-tissue mass in the presacral fossa demonstrated at CT. Twenty-two patients had tumor recurrence; 13 patients had only inflammatory changes or radiation fibrosis. At a single examination of each patient (with no reference to prior baseline studies), MR imaging was more accurate than CT, largely because MR imaging was more successful in the distinction of recurrence from fibrosis based on the differences in signal intensity on T2-weighted images.

Entities:  

Mesh:

Year:  1988        PMID: 3393651     DOI: 10.1148/radiology.168.2.3393651

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  [Improvements in detection of rectal cancer recurrence by multiplanar reconstruction].

Authors:  C A Stückle; K F Haegele; M Jendreck; R Kickuth; O Schneider; G Hohlbach; D Liermann
Journal:  Radiologe       Date:  2005-10       Impact factor: 0.635

2.  Rectal carcinoma: preoperative staging and detection of postoperative local recurrence with transrectal and transvaginal ultrasound.

Authors:  M Scialpi; R Andreatta; S Agugiaro; F Zottele; M Niccolini; F Dalla Palma
Journal:  Abdom Imaging       Date:  1993

3.  Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.

Authors:  C E Neal; T L Swan; M R Baker; R L Ellis; J G Katterhagen
Journal:  Gastrointest Radiol       Date:  1991

4.  Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma.

Authors:  A Toma; E Otsuji; Y Kuriu; K Okamoto; D Ichikawa; A Hagiwara; H Ito; T Nishimura; H Yamagishi
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.